Navigation Links
ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
Date:2/14/2011

CHICAGO, Feb. 14, 2011 /PRNewswire/ -- Zoledronic acid (sold by Novartis as Zometa, Aclasta, and Reclast) is used to treat Osteoporosis, Tumor Metastasis, and Paget's Disease with sales of $2 billion a year.(1)  It is associated with side effects such as post-dose syndrome and osteonecrosis of the jaw.  A new patented method from Dr. Ketan Desai enables the administration of Zoledronic acid in combination with another drug that relieves the side effects.

(Logo:  http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

This patented method will be auctioned off at ICAP Ocean Tomo's Spring 2011 Live IP Auction on March 31, 2011 in New York City. Key Characteristics of MethodThe patents disclose the following:


  • Method enables administration of zoledronic acid in a novel combination.
  • Method results in decreased side effects.
  • Can be administered though different methods: oral supply, inhalation, muscle injection, or veindrip.
  • Market OverviewThese patents may be of interest in the following areas:


  • The global market for pain management pharmaceuticals and devices amounted to $19.1 billion in 2008 and is expect to reach $32.8 billion in 2013.(2)
  • These patents would be of interest to: pharmaceutical companies, drug manufacturers, healthcare service providers, and biomedical research.
  • To learn more about the assets available for sale in this portfolio: Contact Dean Becker of ICAP Ocean Tomo at Dean.Becker@us.icap.comAbout ICAP Ocean Tomo LLCICAP Ocean Tomo is the intellectual property brokerage division of ICAP and the world's premier patent auction firm.

    About ICAPICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.

    (1) http://www.thepharmaletter.com/file/100554/novartis-zometa-fails-to-meet-ph-iii-primary-endpoint-in-early-breast-cancer-stalling-this-indication-but-afinitor-looks-good.html

    (2) http://www.bccresearch.com/report/HLC026C.html


    '/>"/>

    SOURCE ICAP Ocean Tomo
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cutting Edge Nanotech Patents for Displays, Lighting, X-ray, Medical Imaging, and Diagnostics Available for Sale by ICAP Ocean Tomo
    2. ICAP Ocean Tomo to Auction 7 Exclusive Licenses from Lawrence Livermore National Laboratory at Fall Auction November 11th in Napa, California
    3. Skin Lesion Identification System to Auction on November 11th at ICAP Ocean Tomos Fall 2010 Live IP Auction
    4. ICAP Ocean Tomo Offers for Sale IP Portfolio of Active Implants for Electromagnetic Bone and Tissue Regeneration in Orthopedics, Trauma, and Wound Care
    5. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
    6. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
    7. Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
    8. Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
    9. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
    10. Dynatronics Announces Fiscal Second Quarter Results
    11. K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/29/2017)... New York , March 29, 2017 /PRNewswire/ ... recently published a report, which provides an exhaustive ... to the study, nearly 242 companies are functional ... fragmented and competitive. With the leading companies, such ... Purdue Pharma LP, focusing aggressively on various marketing ...
    (Date:3/29/2017)... Research and Markets has announced the addition of the ... ... drugs market to grow at a CAGR of 2.87% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
    (Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
    Breaking Medicine Technology:
    (Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up to 36% ... other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors ... finding more effective treatment options, the San Diego Gamma Knife Center offers ...
    (Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in 2009 ... have participated in the program every summer. The 2017 Serve, Learn, & Empower ... Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my daughter ...
    (Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental ... new patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, ... see the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, ...
    (Date:3/29/2017)... ... March 29, 2017 , ... How big is ... facilities, and who are the most active developers? , In the first ... Real Estate Insights (HREI) found that outpatient medical real estate development projects totaling ...
    (Date:3/29/2017)... Linda, Ca (PRWEB) , ... March 29, 2017 ... ... standard process in many scientific laboratories. The assembly protocols involve many repetitive steps ... well suited for automation, which enables the high-throughput needed, and results in a ...
    Breaking Medicine News(10 mins):